Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
8.76
+0.06 (0.69%)
At close: Jan 16, 2026, 4:00 PM EST
8.70
-0.06 (-0.68%)
After-hours: Jan 16, 2026, 7:51 PM EST
Organon & Co. Employees
Organon & Co. had 10,000 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
10,000
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$630,100
Profits / Employee
$50,100
Market Cap
2.28B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 10,000 | 0 | - |
| Dec 31, 2023 | 10,000 | 0 | - |
| Dec 31, 2022 | 10,000 | 700 | 7.53% |
| Dec 31, 2021 | 9,300 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
OGN News
- 1 day ago - Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque - Business Wire
- 10 days ago - Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway - Business Wire
- 6 weeks ago - Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - Organon To Present at the Piper Sandler 37th Annual Healthcare Conference - Business Wire
- 2 months ago - Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US - Business Wire
- 2 months ago - Organon: Q3 Earnings Lift Struggling Stock - But Not For Long, I Suspect - Seeking Alpha
- 2 months ago - Organon Analysts Cut Their Forecasts Following Q3 Results - Benzinga
- 2 months ago - Organon & Co. (OGN) Q3 2025 Earnings Call Transcript - Seeking Alpha